Generic name |
levodopa-carbidopa |
|
---|---|---|
Strength & form |
20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate intestinal gel |
Special Authority criteria |
Approval period |
---|---|
InitialFor the management of severe cases of advanced idiopathic Parkinson’s Disease (PD) when requested by a neurologist practicing at a movement disorder clinic AND all criteria below are met:
AND
AND
AND
AND
|
1 year
|
RenewalThe patient continues to benefit from the treatment, including significant reduction in the time spent in the off state and/or in ongoing, bothersome levodopa-induced dyskinesias, along with an improvement in the severity of the disability in the off state. |
1 year |